The Fraud of Biological Psychiatry Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The Fraud of Biological Psychiatry

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: AugustWest who wrote (304)	1/16/2002 10:53:09 PM
From: AugustWest	of 444

Celltech to increase US sales presence Wednesday, April 11, 2001 Celltech is to increase its US salesforce by almost 40% to support newly approved Metadate its ADHD (Attention Deficit Hyperactivity Disorder) drug due to be marketed by autumn. Metadate’s marketing advantage is that it is the first once-a-day formulation of the generic drug methylphenidate easing demands on the child patients parents and teachers. The global market for hyperactivity disorder products is approximately $800 million the vast majority of it in the US. Metadate’s main rivals will be Shire’s Adderall and Alza’s Concerta. Celltech’s Chief Executive expects the launch of Metadate to prompt Alza (recently bought by Johnson & Johnson) to increase its salesforce as well. Shire is expected to respond by producing a once-daily formulation of Adderall to capture the lion’s share of the lucrative market. pharmafile.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next